Nucleix Stock
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests.
Sign up today and learn more about Nucleix Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Nucleix Stock
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
Funding History
| January 2015 | $50K |
|---|---|
| May 2016 | $3.0M |
| July 2018 | $2.5M |
| April 2021 | $55.0M |
| January 2022 | $22.0M |
Management
Co-founder, VP Software & Analytics
Adam Wasserstrom
VP Research & Co-founder
Danny Frumkin
Chief Executive Officer
Chris Hibberd
Member of Board of Directors
Dan J. Gelvan
Chief Financial Officer
W. Todd Myers
Executive Chairman
Chris Hibberd
Press
biospace - Nov, 8 2023
Nucleix Receives Reimbursement for Bladder EpiCheck® in the Netherlandsbiospace - Oct, 11 2023
Nucleix Advances Early Lung Cancer Detection Program with Promising Performance Data and Appointment of Chief Scientific Officergenomeweb - Jun, 10 2023
People in the News at Biocartis, Angle, Nucleix, Almaden Genomics, SomaLogic, Morebiospace - Jun, 8 2023
Nucleix Appoints Michael G. Vicari as Chief Commercial Officersdbj - Jan, 19 2022
Nucleix Closes $55M Funding Roundjewishbusinessnews - Jan, 7 2022
Nucleix Raises $77 Million for New Lung Cancer Detection Techsdbj - Apr, 27 2021
Nucleix Raises $55M for Early Detection of Lung Cancergenomeweb - Apr, 9 2021
Nucleix Raises $55M in Financing Roundsocaltech - Apr, 7 2021
Nucleix Nabs $55M For Lung Cancer DetectionEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
